A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose of the combination of gilteritinib and venetoclax that can be given to patients with acute myeloid leukemia (AML) that has returned after prior treatment or has failed to respond to prior treatment. Researchers also want to learn if the study drugs can help to control the disease.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Gilteritinib, Venetoclax
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: AbbVie Inc.
IRB Review and Approval Date: 11/29/2018
Recruitment Status: Open
Projected Accrual: 52
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
Phase I/Phase II
For general questions about clinical trials: